The Hen or the Egg: Inflammatory Aspects of Murine MPN Models

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Jutzi, Jonas S ^a,b   Pahl, Heike L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; PROSTAGLANDIN E2;

ARTICLE; AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MOLECULAR PATHOLOGY; MURINE MODEL; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; IMMUNE SYSTEM; LEUKEMIA, MYELOID; METABOLISM; MOUSE; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LEUKEMIA, MYELOID; MICE; MYELOPROLIFERATIVE DISORDERS;

EID: 84945950010     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/101987     Document Type: Article

References (75)

1. R. Virchow, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin, Georg Reimer, Berlin, Germany, 1869.
2. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: The next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
3. C. Catassi, I. Bearzi, and G. K. T. Holmes, "Association of celiac disease and intestinal lymphomas and other cancers, " Gastroenterology, vol. 128, supplement 1, no. 4, pp. S79-S86, 2005.
4. M. Lukas, "Inflammatory bowel disease as a risk factor for colorectal cancer, " Digestive Diseases, vol. 28, no. 4-5, pp. 619-624, 2010.
5. Y. Shinomura, K. Kinoshita, S. Tsutsui, and S. Hirota, "Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors, " Journal of Gastroenterology, vol. 40, no. 8, pp. 775-780, 2005.
6. M. H. G. P. Raaijmakers, S. Mukherjee, S. Guo et al., "Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia, " Nature, vol. 464, no. 7290, pp. 852-857, 2010.
7. H. C. Hasselbalch, "Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?" Blood, vol. 119, no. 14, pp. 3219-3225, 2012.
8. H. C. Hasselbalch, "A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?" Leukemia Research, vol. 38, no. 2, pp. 263-266, 2014.
9. S. Y. Kristinsson, M. Björkholm, M. Hultcrantz, ? A. R. Derolf, O. Landgren, and L. R. Goldin, "Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes, " Journal of Clinical Oncology, vol. 29, no. 21, pp. 2897-2903, 2011.
10. H. Takizawa, S. Boettcher, and M. G. Manz, "Demand-adapted regulation of early hematopoiesis in infection and inflammation, " Blood, vol. 119, no. 13, pp. 2991-3002, 2012.
11. X. Li, K. M. Kolltveit, L. Tronstad, and I. Olsen, "Systemic diseases caused by oral infection, " Clinical Microbiology Reviews, vol. 13, no. 4, pp. 547-558, 2000.
12. B. L. Esplin, T. Shimazu, R. S. Welner et al., "Chronic exposure to a TLR ligand injures hematopoietic stem cells, " The Journal of Immunology, vol. 186, no. 9, pp. 5367-5375, 2011.
13. K. Sudo, H. Ema, Y. Morita, and H. Nakauchi, "Age-associated characteristics ofmurine hematopoietic stern cells, " The Journal of Experimental Medicine, vol. 192, no. 9, pp. 1273-1280, 2000.
14. S. J. Morrison, A. M. Wandycz, K. Akashi, A. Globerson, and I. L. Weissman, "The aging of hematopoietic stem cells, " Nature Medicine, vol. 2, no. 9, pp. 1011-1016, 1996.
15. M. Kim, H.-B. Moon, and G. J. Spangrude, "Major age-related changes of mouse hematopoietic stem/progenitor cells, " Annals of theNew York Academy of Sciences, vol. 996, pp. 195-208, 2003.
16. R. A. J. Signer, E. Montecino-Rodriguez, O. N. Witte, J. McLaughlin, and K. Dorshkind, "Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia, " Blood, vol. 110, no. 6, pp. 1831-1839, 2007.
17. Y. Lin, S. Chen, and J. Wang, "Critical role of IL-6 in dendritic cell-induced allergic inflammation of asthma, " Journal ofMolecular Medicine, 2015.
18. S. Y. Kristinsson, O. Landgren, J. Samuelsson, M. Björkholm, and L. R. Goldin, "Autoimmunity and the risk of myeloproliferative neoplasms, " Haematologica, vol. 95, no. 7, pp. 1216-1220, 2010.
19. G. Barosi, U. Magrini, and R. P. Gale, "Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associatedmyelofibrosis?" Leukemia Research, vol. 34, no. 9, pp. 1119-1120, 2010.
20. W. Barcellini, A. Iurlo, T. Radice et al., "Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns, " Leukemia Research, vol. 37, no. 11, pp. 1509-1515, 2013.
21. M.-C. Martyre, H. Magdelenat, M.-C. Bryckaert, C. Laine-Bidron, and F. Calvo, "Increased intraplatelet levels of plateletderived growth factor and transforming growth factor-in patients with myelofibrosis with myeloid metaplasia, " British Journal of Haematology, vol. 77, no. 1, pp. 80-86, 1991.
22. S. Hermouet, A. Godard, D. Pineau et al., "Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera, " Cytokine, vol. 20, no. 4, pp. 178-183, 2002.
23. K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta et al., "Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases, " British Journal ofHaematology, vol. 130, no. 5, pp. 709-715, 2005.
24. A. Allegra, A. Alonci, G. Bellomo et al., "Evaluation of Interleukin-17 serum levels in patients with chronic myeloproliferative diseases, " Tumori, vol. 95, no. 3, pp. 404-405, 2009.
25. M. Boissinot, C. Cleyrat, M. Vilaine, Y. Jacques, I. Corre, and S. Hermouet, "Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F, " Oncogene, vol. 30, no. 8, pp. 990-1001, 2011.
26. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, "Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primarymyelofibrosis: A comprehensive cytokine profiling study, " Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356-1363, 2011.
27. S. Verstovsek, H. Kantarjian, R. A. Mesa et al., "Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, " The New England Journal of Medicine, vol. 363, no. 12, pp. 1117-1127, 2010.
28. A. G. Fleischman, K. J. Aichberger, S. B. Luty et al., "TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms, " Blood, vol. 118, no. 24, pp. 6392-6398, 2011.
29. A. M. Vannucchi, L. Bianchi, C. Cellai et al., "Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice), " Blood, vol. 100, no. 4, pp. 1123-1132, 2002.
30. M. Zingariello, F. Martelli, F. Ciaffoni et al., "Characterization of the TGF-1 signaling abnormalities in the Gata1low mouse model of myelofibrosis, " Blood, vol. 121, no. 17, pp. 3345-3363, 2013.
31. H. Chagraoui, E. Komura, M. Tulliez, S. Giraudier, W. Vainchenker, and F. Wendung, "Prominent role of TGF-1 in thrombopoietin-inducedmyelofibrosis in mice, " Blood, vol. 100, no. 10, pp. 3495-3503, 2002.
32. K. B. Kaufmann, A. Gründer, T. Hadlich et al., "A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2, " Journal of Experimental Medicine, vol. 209, no. 1, pp. 35-50, 2012.
33. J. S. Jutzi, R. Bogeska, G. Nikoloski et al., "MPN patients harbor recurrent truncating mutations in transcription factor NF-E2, " Journal of Experimental Medicine, vol. 210, no. 5, pp. 1003-1019, 2013.
34. H. Oshima and M. Oshima, "The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models, " Journal of Gastroenterology, vol. 47, no. 2, pp. 97-106, 2012.
35. M. Oshima, J. E. Dinchuk, S. L. Kargman et al., "Suppression of intestinal polyposis in ?716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), " Cell, vol. 87, no. 5, pp. 803-809, 1996.
36. M. Sonoshita, K. Takaku, N. Sasaki et al., "Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc?716 knockout mice, " Nature Medicine, vol. 7, no. 9, pp. 1048-1051, 2001.
37. M. Nakanishi, D. C. Montrose, P. Clark et al., "Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis, " Cancer Research, vol. 68, no. 9, pp. 3251-3259, 2008.
38. S.-J. Myung, R. M. Rerko, M. Yan et al., "15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 32, pp. 12098-12102, 2006.
39. W.-J. Chae, T. F. Gibson, D. Zelterman, L. Hao, O. Henegariu, and A. L. M. Bothwell, "Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis, " Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 107, no. 12, pp. 5540-5544, 2010.
40. S. Grivennikov, E. Karin, J. Terzic et al., "IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, " Cancer Cell, vol. 15, no. 2, pp. 103-113, 2009.
41. B. K. Popivanova, F. I. Kostadinova, K. Furuichi et al., "Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice, " Cancer Research, vol. 69, no. 19, pp. 7884-7892, 2009.
42. B. K. Popivanova, K. Kitamura, Y. Wu et al., "Blocking TNF-in mice reduces colorectal carcinogenesis associated with chronic colitis, " The Journal of Clinical Investigation, vol. 118, no. 2, pp. 560-570, 2008.
43. M. A. Al-Salihi, A. Terrece Pearman, T. Doan et al., "Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression, " Cancer Letters, vol. 273, no. 2, pp. 225-232, 2009.
44. T.-O. Ishikawa, M. Oshima, and H. R. Herschman, "Cox-2 deletion in myeloid and endothelial cells, but not in epithelialcells, exacerbates murine colitis, " Carcinogenesis, vol. 32, no. 3, pp. 417-426, 2011.
45. V. M. Zaleskas, D. S. Krause, K. Lazarides et al., "Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F, " PLoS ONE, vol. 1, article e18, 2006.
46. Y. Pikman, B. H. Lee, T. Mercher et al., "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia, " PLoS Medicine, vol. 3, no. 7, article e270, 2006.
47. C. Marty, C. Lacout, A. Martin et al., "Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice, " Blood, vol. 116, no. 5, pp. 783-787, 2010.
48. R. Tiedt, H. Hao-Shen, M. A. Sobas et al., "Ratio of mutant JAK2-V617F to wild-type Jak2 determines theMPD phenotypes in transgenic mice, " Blood, vol. 111, no. 8, pp. 3931-3940, 2008.
49. Z. Li, X. Cai, C.-L. Cai et al., "Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies, " Blood, vol. 118, no. 17, pp. 4509-4518, 2011.
50. S. Hasan, C. Lacout, C. Marty et al., "JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha, " Blood, vol. 122, no. 8, pp. 1464-1477, 2013.
51. J. Wang, Z. Li, Y. He et al., "Loss of Asxl1 leads tomyelodysplastic syndrome-like disease in mice, " Blood, vol. 123, no. 4, pp. 541-553, 2014.
52. T. Muto, G. Sashida, N. Hasegawa et al., "Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice, " Leukemia & Lymphoma, vol. 56, no. 2, pp. 520-523, 2015.
53. P. S. Goerttler, C. Kreutz, J. Donauer et al., "Gene expression profiling in polycythaemia vera: Overexpression of transcription factor NF-E2, " British Journal of Haematology, vol. 129, no. 1, pp. 138-150, 2005.
54. W. Wang, S. Schwemmers, E. O. Hexner, and H. L. Pahl, "AML1 is overexpressed in patients with myeloproliferative neoplasms andmediates JAK2V617F-independent overexpression ofNF-E2, " Blood, vol. 116, no. 2, pp. 254-266, 2010.
55. C. K. Y. Chuen, K. Li, M. Yang et al., "Interleukin-1 upregulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells, " Journal of Laboratory and Clinical Medicine, vol. 143, no. 2, pp. 75-88, 2004.
56. J. Wehrle, T. Seeger, S. Schwemmers, D. Pfeifer, A. Bulashevska, and H. Pahl, "Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms, " Haematologica, vol. 98, no. 7, pp. 1073-1080, 2013.
57. R. Roelz, I. H. Pilz, M. Mutschler, and H. L. Pahl, "Of mice and men: human RNA polymerase III promoter U6 is more efficient than itsmurine homologue for shRNAexpression from a lentiviral vector in both human and murine progenitor cells, " Experimental Hematology, vol. 38, no. 9, pp. 792-797, 2010.
58. A. B. Sparks, P. J. Morin, B. Vogelstein, and K. W. Kinzler, "Mutational analysis of the APC/-catenin/Tcf pathway in colorectal cancer, " Cancer Research, vol. 58, no. 6, pp. 1130-1134, 1998.
59. J. Groden, A. Thliveris, W. Samowitz et al., "Identification and characterization of the familial adenomatous polyposis coli gene, " Cell, vol. 66, no. 3, pp. 589-600, 1991.
60. A. Mullally, S. W. Lane, B. Ball et al., "Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells, " Cancer Cell, vol. 17, no. 6, pp. 584-596, 2010.
61. T.-O. Ishikawa and H. R. Herschman, "Tumor formation in a mousemodel of colitis-associated colon cancer does not require COX-1 or COX-2 expression, " Carcinogenesis, vol. 31, no. 4, pp. 729-736, 2010.
62. E. Gounaris, S. E. Erdman, C. Restaino et al., "Mast cells are an essential hematopoietic component for polyp development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 50, pp. 19977-19982, 2007.
63. P. Ramos, C. Casu, S. Gardenghi et al., "Macrophages support pathological erythropoiesis in polycythemia vera and betathalassemia, " Nature Medicine, vol. 19, no. 4, pp. 437-445, 2013.
64. I. Corre-Buscail, D. Pineau, M. Boissinot, and S. Hermouet, "Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8, " Experimental Hematology, vol. 33, no. 11, pp. 1299-1308, 2005.
65. M. Howlett, A. S. Giraud, H. Lescesen et al., "The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development, " Gastroenterology, vol. 136, no. 3, pp. 967. e3-977. e3, 2009.
66. S. Hermouet, I. Corre, and E. Lippert, "Interleukin-8 and other agonists of gi2 proteins: Autocrine paracrine growth factors for human hematopoietic progenitors acting in synergy with colony stimulating factors, " Leukemia and Lymphoma, vol. 38, no. 1-2, pp. 39-48, 2000.
67. A. M. Vannucchi, A. Pancrazzi, P. Guglielmelli et al., "Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis, " The American Journal of Pathology, vol. 167, no. 3, pp. 849-858, 2005.
68. F. Ciaffoni, E. Cassella, L. Varricchio, M. Massa, G. Barosi, and A. R. Migliaccio, "Activation of non-canonical TGF-beta1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis, " Blood Cells, Molecules, and Diseases, vol. 54, no. 3, pp. 234-241, 2015.
69. N. Sanderson, V. Factor, P. Nagy et al., "Hepatic expression of mature transforming growth factor 1 in transgenic mice results in multiple tissue lesions, " Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 92, no. 7, pp. 2572-2576, 1995.
70. M. Lu, L. Xia, Y. C. Liu et al., "Lipocalin produced bymyelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells, " Blood, 2015.
71. J. B. Cowland, O. E. Sørensen, M. Sehested, and N. Borregaard, "Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1, but not by TNF-, " The Journal of Immunology, vol. 171, no. 12, pp. 6630-6639, 2003.
72. F. Shen, M. J. Ruddy, P. Plamondon, and S. L. Gaffen, "Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17-and TNF-induced genes in bone cells, " Journal of Leukocyte Biology, vol. 77, no. 3, pp. 388-399, 2005.
73. M.-J. Xu, D. Feng, H. Wu et al., "Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: A critical role for IL-6/STAT3, " Hepatology, vol. 61, no. 2, pp. 692-702, 2015.
74. M. J. Thun, M. M. Namboodiri, and C. W. Heath Jr., "Aspirin use and reduced risk of fatal colon cancer, "TheNew England Journal of Medicine, vol. 325, no. 23, pp. 1593-1596, 1991.
75. R. Landolfi, R. Marchioli, J. Kutti et al., "Efficacy and safety of low-dose aspirin in polycythemia vera, " The New England Journal of Medicine, vol. 350, no. 2, pp. 114-124, 2004.